Site Editors

Shaji K. Kumar, MD

Prashant Kapoor, MD, FACP


ASH 2023: Large Real-World Study of Bispecific T-Cell Engager in Resistant Myeloma

By: Jenna Carter, PhD
Posted: Tuesday, December 12, 2023

In a study presented at the 2023 American Society for Hematology (ASH) Annual Meeting & Exposition (Abstract 91), researchers assessed the real-world safety and efficacy of teclistamab-cqyv, a B-cell maturation antigen–targeting bispecific T-cell engager. Danai Dima, MD, of Taussig Cancer Institute, Cleveland Clinic, and colleagues reported that after a median follow-up of 3.2 months, the overall response rate was 64% for the entire cohort; Additionally, the rates of estimated 6-month progression free survival, duration of response, and overall survival for the entire cohort were 38%, 54%, and 68%, respectively. There were also no reports of treatment-related mortality; however, 89% of deaths were attributed to disease progression.

“In this multicenter retrospective study, we evaluated the… safety and efficacy of teclistamab, highlighting patterns of utilization and outcomes, including patients who would have been considered ineligible for MajesTEC-1 trial,” stated Dr. Dima and colleagues.

A total of 102 patients with relapsed or refractory multiple myeloma were enrolled in this study. Teclistamab was administered in a step-up dosing manner, and all patients received at least two step-up doses and the first full dose of the drug.

Overall findings revealed that grade 1 or 2 events were reported in most patients; however, there were reports of grade 3 or 4 events in three patients, the most common being neutropenia (23%), leukopenia (18%), thrombocytopenia (17%), and anemia (17%). Additionally, infections were reported in 28% of the patients, half of which were characterized as severe. The estimated 6-month progression-free survival and overall survival rates for the entire cohort were 38% (95% confidence interval [CI] = 26%–56%) and 68% (95% CI = 58%–80%), respectively. Based on these findings, the researchers concluded that teclistamab was well tolerated and had no major safety concerns.

Disclosure: For full disclosures of the study authors, visit

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.